Stapokibart is under clinical development by KeyMed Biosciences and currently in Phase III for Prurigo. According to GlobalData, Phase III drugs for Prurigo have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Stapokibart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Stapokibart overview

Stapokibart (Kangyueda) is a humanized monoclonal antibody. It is formulated as a solution for the subcutaneous route of administration. Kangyueda is indicated for the treatment of moderate to severe atopic dermatitis in adults who are poorly controlled by topical medications or are not suitable for topical medications.
CM-310 is under development for the treatment of atopic dermatitis in children and adolescents, mild to moderate asthma, prurigo nodularis, chronic rhinosinusitis with nasal polyps, allergic rhinitis, chronic obstructive pulmonary disease (COPD). It is administered through subcutaneous route. The drug candidate acts by targeting interleukin 4 receptor subunit alpha.
It was also under development for chronic pruritus.

KeyMed Biosciences overview

KeyMed Biosciences engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. The company is headquartered in Chengdu, Sichuan, China.

For a complete picture of Stapokibart’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.